CN Mobile Logo

Search form


Head & Neck Cancer

Head & Neck Cancer

Adherence to each of five quality metrics for head and neck squamous cell carcinoma was associated with a reduced risk for death.

Higher nodal yield during definitive surgery for clinically node-negative oral cavity squamous cell carcinoma was associated with improved mortality.

Three-weekly cisplatin is superior to a weekly dose in preventing locoregional relapse when combined with radiotherapy in head and neck squamous cell carcinoma.

Patients with recurrent or metastatic squamous cell carcinoma of the head and neck treated with the checkpoint inhibitor nivolumab were able to maintain baseline levels of quality of life.

The addition of two cycles of neoadjuvant chemotherapy to concurrent chemoradiotherapy improved tumor control in patients with nasopharyngeal carcinoma.

This video reviews results of LUX-Head & Neck 2, a randomized phase III trial that studied afatinib as adjuvant therapy in patients with unresected squamous cell head and neck cancer.

This video highlights results of a phase III randomized trial that tested chemotherapy plus bevacizumab in patients with recurrent or metastatic head and neck cancer.


Subscribe to Head & Neck Cancer on [sitename]

By clicking Accept, you agree to become a member of the UBM Medica Community.